CDK4/6 signaling pathway and its targeted therapeutic agents in cancer therapy: a review.

Ziqi LIU; Tao ZUO; Feng XU; Ping XU

Return

CDK4/6 signaling pathway and its targeted therapeutic agents in cancer therapy: a review.

Author: Ziqi LIU ¹ ; Tao ZUO ¹ ; Feng XU ¹ ; Ping XU ¹
Author Information

1. State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Institute of Lifeomics, Academy of Military Medical Sciences of Academy of Military Science, Beijing 102206, China.
Publication Type:Review
Keywords: CDK4/6; CDK4/6 inhibitor; drug resistance; neoplasm
MeSH: Breast Neoplasms; Cyclin-Dependent Kinase 4/therapeutic use*; Cyclin-Dependent Kinase 6/therapeutic use*; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors/therapeutic use*; Signal Transduction
From: Chinese Journal of Biotechnology 2021;37(7):2232-2239
CountryChina
Language:Chinese
Abstract: The development and progression of most cancers have been well recognized as the result of highly activated cell cycle. Cyclin dependent kinase 4/6 plays important roles not only in mitosis, but also in multiple biological processes that contribute to cancer development, such as aging, apoptosis and histone modification. Three FDA approved CDK4/6 inhibitors, Palbociclib, Ribociclib and Abemaciclib, have been used as targeted cancer therapeutic agents to benefit patients with endocrine therapy-resistant breast cancer and other types of cancer, prolonging their survival. However, the clinical application of these inhibitors also leads to acquired drug resistance and other problems. This paper reviews the regulatory roles of CDK4/6, the application of CDK4/6 inhibitors in cancer and the challenge of drug resistance.